KFF Finds TrumpRx Prices Are a Mixed Bag Compared to Other Countries

TrumpRx, a federal website launched to publish drug pricing information, does not consistently beat prices paid in other wealthy nations, according to an analysis published September 24, 2026, by KFF, a nonprofit health policy research organization. KFF compared 32 brand-name drugs listed on TrumpRx, excluding generics and biosimilars, against publicly available prices in one or more of 11 member countries of the Organisation for Economic Co-operation and Development (OECD), a group of 38 mostly high-income countries that includes Canada, Germany, Japan, and the United Kingdom. According to KFF, TrumpRx prices were about as likely to be higher as they were to be lower than the average price in those comparison countries. Read the full analysis at KFF's report on TrumpRx and international drug prices.

TrumpRx was created as part of a federal push to lower drug costs by publishing prices manufacturers agreed to offer directly to consumers, sometimes bypassing insurance. The premise behind the site has been that direct, published pricing would put downward pressure on what Americans pay for brand-name medications, which have historically cost more in the United States than in other developed countries. KFF's comparison tests that premise against real-world pricing data rather than assuming it holds true across the board.

Key Takeaway

KFF's analysis of 32 brand-name drugs found TrumpRx prices split roughly evenly between higher and lower compared to 11 other OECD countries. That means the site is not a guaranteed source of the lowest price for a given medication, and Medicare enrollees should still compare TrumpRx against their plan's formulary price, manufacturer coupons, and pharmacy discount programs before assuming they are getting the best deal.

Why a Mixed Result Is More Useful Than a Simple Win or Loss

A finding that prices are split roughly 50/50 is more informative for shoppers than a claim that TrumpRx is always cheaper, because it tells readers the site's value depends on the specific drug being priced. KFF's methodology compared listed TrumpRx prices to average prices reported in one or more of 11 specific OECD countries, which means results can vary by drug and by which countries had available pricing data. The analysis did not include generic drugs or biosimilars, so it says nothing about pricing for the lower-cost drug categories that make up a large share of what many seniors actually take.

What This Means for Medicare Enrollees and Their Families

For Senior Plan Path readers managing prescription costs alongside a Medicare Part D or Medicare Advantage plan, KFF's findings reinforce a practical rule: check the price in more than one place before paying out of pocket. TrumpRx may list a competitive price for some brand-name drugs, but KFF's analysis shows it is not a default discount for every medication. Before assuming TrumpRx offers savings, compare it against your plan's negotiated formulary price, since your out-of-pocket cost under Part D or Medicare Advantage may already reflect a plan-negotiated rate that differs from a direct-to-consumer listing. It is also worth checking whether a drug purchased through TrumpRx counts toward your plan's deductible or true out-of-pocket spending, since paying outside your plan can affect how quickly you reach catastrophic coverage under Medicare's redesigned Part D benefit structure.

Manufacturer patient assistance programs and pharmacy discount cards, such as those offered independently of TrumpRx, remain worth checking for brand-name drugs, particularly for medications not yet listed on the site. Because KFF's comparison excluded generics and biosimilars, which typically cost far less than brand-name equivalents, readers should ask their prescriber or pharmacist whether a generic or biosimilar alternative exists before assuming a brand-name TrumpRx price is the best available option.

What to Watch Next

KFF's analysis covers a snapshot of 32 drugs as of its September 2026 publication date, and the list of medications and countries included in future comparisons may expand. Readers should watch for updated KFF analyses or federal statements about how many drugs TrumpRx lists and whether pricing coverage grows to include generics. In the meantime, the most reliable step for anyone comparing costs is to check the current price for a specific medication directly through TrumpRx, their Part D or Medicare Advantage plan's formulary tool, and a pharmacy benefit comparison, rather than relying on a general assumption that any single source is always the cheapest. A licensed Medicare agent or State Health Insurance Assistance Program (SHIP) counselor can help compare these options for a specific drug list at no cost to the enrollee.